Keyphrases
Phase II Study
100%
Resectable Pancreatic Cancer
100%
Antifolate
100%
Pemetrexed Disodium
100%
LY231514
100%
Pancreatic Cancer
40%
Phase II Trial
40%
Antitumor Activity
20%
Anemia
20%
Neutropenia
20%
Dose Reduction
20%
Nonhematologic
20%
2-cycles
20%
1-year Survival
20%
Treatment Delay
20%
Skin Reactions
20%
Hematotoxicity
20%
Thrombocytopenia
20%
Metastatic Disease
20%
Median Survival
20%
Bilirubin
20%
Stable Disease
20%
Survival Time
20%
Transaminases
20%
New Agents
20%
Infectious Complications
20%
Metastatic Pancreatic Cancer
20%
Objective Response Rate
20%
Indianapolis
20%
Eli Lilly
20%
Combination Trials
20%
Chemotherapy-naïve Patients
20%
Partial Duration
20%
Medicine and Dentistry
Pancreas Cancer
100%
Pemetrexed
100%
Antifolate
100%
Phase II Trials
28%
Neutropenia
14%
Infusion
14%
Anemia
14%
Metastatic Carcinoma
14%
Bilirubin
14%
Skin Manifestation
14%
Infectious Complication
14%
Antineoplastic Activity
14%
Thrombocytopenia
14%
Transaminase
14%
Dexamethasone
14%
Survival Time
14%
Drug Dose Reduction
14%
Therapy Delay
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Pemetrexed
100%
Folic Acid Antagonist
100%
Phase II Trials
28%
Dexamethasone
14%
Anemia
14%
Neutropenia
14%
Chemotherapy
14%
Thrombocytopenia
14%
Infectious Complication
14%
Antitumor Activity
14%
Aminotransferase
14%
Bilirubin
14%
Survival Time
14%
Skin Manifestation
14%
Diseases
14%